EUVIMEDEUVIMED entdecken
Open Access

Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy

Sonali Mitra, Hee-Jin Jang, Allen Kuncheria, Sung Wook Kang, Jong Min Choi, Ji Seon Shim, Claire Lee, Priyanka Ranchod, Peter Jindra, Maheshwari Ramineni, Meera Patel, R Taylor Ripley und 4 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2025

DOI: 10.1016/j.jtcvs.2024.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Sonali Mitra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Systems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Med…. Hauptthemen laut MEDLINE: Pleural Neoplasms, Mesothelioma, Malignant, GPI-Linked Proteins, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint therapy (ICT) has significantly impacted the treatment of malignant pleural mesothelioma (MPM). Despite some promising results from combination therapies, nearly half of MPM patients do not benefit, underscoring the urgent need for reliable predictive biomarkers. This study assesses the prognostic value of serum soluble mesothelin-related peptide (SMRP) and PD-L1 levels in MPM patients receiving ICT. METHODS: We conducted a retrospective analysis of 125 MPM patients treated with ICT by measuring pre-ICT serum levels of SMRP and PD-L1. We also examined the correlation of these serum levels with tumor mRNA expressions of mesothelin and PD-L1. Both univariable and multivariable Cox regression analyses were used to determine independent prognosticators for overall survival (OS). A prospective ICT clinical trial and our historical cohort were included for validation. RESULTS: Seventy-seven patients (62%) were treated with either anti-PD-(L)1 monotherapy, and the remaining 38% received combination ICT. Higher pre-ICT SMRP levels were observed in epithelioid MPM compared to nonepithelioid MPM. Serum PD-L1 levels did not differ significantly between the different histologic groups. Univariable analysis identified durable clinical benefit, development of immune-related adverse events, and SMRP levels as significantly associated with OS. Multivariable analysis confirmed SMRP as an independent prognostic factor, with lower levels (≤1.35 nmol/L) correlating with improved OS. The association of high SMRP with worse prognosis was validated in the prospective ICT clinical trial cohort and not in our historical cohort treated without ICT. CONCLUSIONS: SMRP is a promising serum biomarker for predicting survival in MPM patients treated with ICT and warrants prospective investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pleural NeoplasmsMesothelioma, MalignantGPI-Linked ProteinsBiomarkers, TumorImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMesotheliomaHumansMaleFemaleMesothelinMiddle AgedAgedRetrospective StudiesB7-H1 AntigenTreatment OutcomePredictive Value of Tests

Stichwörter der Autor:innen

SMRPcheckpoint immunotherapyliquid biomarkermesotheliomaprognostic biomarkersoluble PD-L1

Substanzen

MesothelinGPI-Linked ProteinsBiomarkers, TumorImmune Checkpoint InhibitorsB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Systems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex.
  • Immune Evaluation Laboratory, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex.
  • Department of Pathology, Baylor College of Medicine, Houston, Tex; Dan L Ducan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Tex.
  • Dan L Ducan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Tex; Division of Hemato-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex.
  • Dan L Ducan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Tex; David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex.
  • Systems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Division of Thoracic Surgery, David Geffen School…

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • National Cancer Institute
  • U.S. Department of Defense
  • US Department of Defense Peer Reviewed Cancer Research Program
  • Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
  • Cancer Prevention and Research Institute of Texas
  • Lions Medical Research Foundation

Zitieren

APA

Mitra, S., Jang, H. J., Kuncheria, A., Kang, S. W., Choi, J. M., Shim, J. S., Lee, C., Ranchod, P., Jindra, P., Ramineni, M., Patel, M., Ripley, R. T., Groth, S. S., Blackmon, S. H., Burt, B. M., & Lee, H. S. (2025). Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2024.10.005

Vancouver

Mitra S, Jang HJ, Kuncheria A, Kang SW, Choi JM, Shim JS, et al. Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy. The Journal of Thoracic and Cardiovascular Surgery. 2025. doi:10.1016/j.jtcvs.2024.10.005

BibTeX
@article{Mitra2025,
  author = {Mitra, Sonali and Jang, Hee-Jin and Kuncheria, Allen and Kang, Sung Wook and Choi, Jong Min and Shim, Ji Seon and Lee, Claire and Ranchod, Priyanka and Jindra, Peter and Ramineni, Maheshwari and Patel, Meera and Ripley, R Taylor and Groth, Shawn S and Blackmon, Shanda H and Burt, Bryan M and Lee, Hyun-Sung},
  title = {Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2025},
  doi = {10.1016/j.jtcvs.2024.10.005}
}
Kostenlos starten →